Circulating cancer biomarkers
The laboratory aims at investigating the clinical relevance of tumor biomarkers that are related to the tumor dissemination and metastatic process.
-
A new factor in prognosis for metastatic uveal melanomaHow can we achieve a more accurate prognosis for patients after removal of liver metastases from uveal melanoma? By using a differentiating marker, namely circulating tumor DNA. This has just been shown by a study in one of the top surgery journals, Annals of Surgery, involving Institut Curie’s medical and research teams.31/03/2023 -
Institut Curie certified as Integrated cancer research site for the third timeFollowing a call for applications launched in April 2022, Institut Curie had its integrated cancer research site project certified by France’s Institut national du cancer (Inca). Its goal is to better understand tumor recurrences in order to better prevent, detect and treat them.20/02/2023 -
Cancer du sein triple négatif : vers une nouvelle génération de thérapies jamais exploréesParticulièrement impliqué dans la recherche sur le cancer du sein triple négatif, l’Institut Curie mène différents projets pour améliorer les traitements des femmes atteintes de ce type de cancer agressif. Parmi eux, le projet d’envergure CASSIOPEIA.03/03/2022 -
Deux projets portés par l’Institut Curie lauréats du programme RHUDeux projets d'envergure portés par l’Institut Curie sont lauréats du programme Recherche Hospitalo-Universitaire : CASSIOPEIA dans les cancers du sein triple négatifs et EpCART pour les cancers de mauvais pronostic.09/12/2021
Pr. François-Clément Bidard presented the data from the the STIC CTC trial, at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.
The STIC CTC trial is the first to establish the clinical utility of the CTC count as a biomarker in breast cancer care, indicating that a single assessment of the CTC count before the start of treatment can guide the treatment decision between chemotherapy and single agent endocrine therapy in ER-positive/HER2-negative metastatic breast cancer. This study demonstrates that integrating prognostic biomarkers into the treatment algorithm can improve the management and outcomes of metastatic breast cancer patients.
This is a joint study between Curie hospital (Dr Pascale Mariani et al.) and Curie research center (Dr Marc-Henri Stern and our group), recently published in Annals of Surgery.
This study is the first to report ctDNA detection rate and prognostic impact in uveal melanoma patients eligible for surgical resection of their liver metastases.